Positive inotropic agents

Mechanism of Inotropy - The Heart's Power-Up

• Primary Driver: ↑ intracellular Calcium ($Ca^{2+}$) is the final common pathway for inotropy.
• Key Pathway: Sympathetic stimulation of β1 receptors activates the cAMP-PKA pathway.
  • PKA phosphorylates L-type $Ca^{2+}$ channels → ↑ $Ca^{2+}$ influx.
  • PKA also enhances sarcoplasmic reticulum (SR) $Ca^{2+}$ release.

⭐ Digoxin's Unique Mechanism: Unlike sympathomimetics, Digoxin inhibits the Na⁺/K⁺-ATPase pump. This leads to ↑ intracellular Na⁺, which then reduces Ca²⁺ efflux via the Na⁺/Ca²⁺ exchanger, ultimately increasing intracellular $Ca^{2+}$ and contractility.

Cardiac Glycosides - Digoxin's Digital Grip

• Mechanism: Directly inhibits the Na⁺/K⁺ ATPase pump in myocardial cells.
  • This increases intracellular Na⁺, reversing the Na⁺/Ca²⁺ exchanger.
  • Result: ↑ intracellular Ca²⁺ → ↑ contractility (positive inotropy).
  • Also stimulates the vagus nerve → ↓ AV nodal conduction & ↓ heart rate.

• Clinical Use:

  • Heart Failure (HFrEF): For symptomatic control; no survival benefit.
  • Atrial Fibrillation: Rate control by slowing AV conduction.

• Toxicity & Adverse Effects (Narrow Therapeutic Index):

  • Cardiac: Any arrhythmia, classically scooped "hockey-stick" ST segments on ECG.
  • GI/CNS: Nausea, vomiting, confusion, xanthopsia (yellow vision).
  • Antidote: Digoxin immune Fab.

⭐ Hypokalemia is a key precipitant of digoxin toxicity because it reduces competition for binding sites on the Na⁺/K⁺ ATPase.

Beta-Adrenergic Agonists - The Beta Boosters

• Mechanism: Stimulate β-receptors → ↑ adenylyl cyclase → ↑ cAMP → ↑ intracellular Ca²⁺ → ↑ myocardial contractility & heart rate.
• Agents & Actions:
  • Dobutamine: Primarily β₁ agonist. ↑ Contractility >> ↑ Heart Rate. Used in acute decompensated heart failure & cardiogenic shock.
  • Dopamine: Dose-dependent effects.
    • Low: D₁ receptors → Renal vasodilation.
    • Med: β₁ receptors → ↑ Contractility, ↑ HR.
    • High: α₁ receptors → Vasoconstriction.
  • Isoproterenol: Non-selective β₁/β₂ agonist. ↑ HR & contractility, but potent vasodilation (↓ SVR).
• Adverse Effects: Tachyarrhythmias, angina, headache.

⭐ In cardiogenic shock, dobutamine is a primary choice. However, if the patient is severely hypotensive (e.g., SBP < 70 mmHg), dopamine or norepinephrine are preferred for their potent vasoconstrictor effects.

PDE-3 Inhibitors - cAMP's Lifeguards

• Drugs: Milrinone, Inamrinone.
• Mechanism: Selective PDE-3 inhibition prevents cAMP breakdown in cardiac and vascular smooth muscle.
  • Heart: ↑ cAMP → PKA activation → ↑ Ca²⁺ influx → ↑ contractility (inotropy) & heart rate.
  • Vessels: ↑ cAMP → smooth muscle relaxation → significant vasodilation (↓ preload & afterload).
• Use: Short-term management of acute decompensated heart failure.
• Adverse Effects: Ventricular arrhythmias, hypotension, thrombocytopenia.

⭐ Reserved for severe, refractory heart failure as long-term use is associated with increased mortality.

High‑Yield Points - ⚡ Biggest Takeaways

• Digoxin inhibits the Na+/K+ ATPase, increasing intracellular Ca2+ and contractility; toxicity presents with xanthopsia and hyperkalemia.
• Beta-agonists (Dobutamine) and PDE-3 inhibitors (Milrinone) increase cAMP, boosting contractility in acute heart failure.
• Both are used for acute decompensated HF but increase myocardial O2 demand and risk of arrhythmias.
• The final common pathway for inotropy is elevated intracellular calcium.
• Treat digoxin toxicity with DigiFab (antibody fragments).